New York, January 29, 2026, 05:34 EST — Premarket
ENvue Medical shares dropped roughly 10% in early trading Thursday, following a surge of more than 100% the day before. At 5:31 a.m. ET, the stock traded at $2.06, down from Wednesday’s close of $2.30, which had marked a 119% jump. 1
The move is significant since ENvue is a micro-cap stock known for sharp swings on single headlines, and Wednesday’s rally happened on heavy volume. Traders now face the question: does the U-Deliver deal signal ongoing orders and more stable revenue, or is this just a brief burst of interest?
Investors are also watching closely as the company expands into non-acute care—places like home and long-term care—where how products are distributed and accessed can make or break a new launch.
ENvue announced Wednesday it has inked a distribution deal with U-Deliver to roll out its over-the-counter reusable ENFit syringe line across the U.S., targeting non-acute care channels. CEO Doron Besser described the move as “an important step in scaling” the syringe line. U-Deliver President Brian Johnson added the partnership’s goal is to “make tube feeding easier.” 2
The company confirmed that ENFit syringes are now available on U-Deliver’s website and Amazon storefront, as well as through wholesale channels. They come in 2.5 mL, 5 mL, 10 mL, and 60 mL sizes, and can be purchased without a prescription. These syringes are built for reuse—up to seven days or 20 uses—and comply with ISO 80369-3 standards. 3
ISO 80369-3 sets the worldwide standard for small-bore connectors on enteral devices—those used to provide nutrition or medication through the digestive tract, typically with feeding tubes. 4
Wednesday’s surge sparked heavy trading: around 270.5 million shares changed hands, a massive leap from just about 195,000 shares the previous day, per stock data. 5
ENvue, which was known as NanoVibronix, rebranded as ENvue Medical last December, also switching its Nasdaq ticker to “FEED.” The company is focusing on its ENvue feeding-tube placement system, aiming to build out what it calls an “enteral-feeding ecosystem,” according to Besser at the time. 6
The downside is straightforward to outline. The company flagged risks in its filings, including market acceptance, operational hurdles, and “the need for additional capital.” The announcement also left out financial terms and revenue projections tied to the U-Deliver deal. 7
Traders will be watching if Thursday’s early dip deepens after U.S. markets open, and whether volume remains high or fades away. Any new info on timing, pricing, or initial sales through U-Deliver’s channels could send the stock moving again.
All eyes turn to the U.S. cash open at 9:30 a.m. ET, as broader liquidity floods back and the market weighs if Wednesday’s move will stick.
